SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549
____________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 612, 2016 Microlin Bio, Inc. (Exact name of registrant as specified in its charter)

Delaware	000-55425	45-4507811
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

135 East 57th Street, 24th Floor

New York, NY

10022

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (646) 406-6243

___________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)

[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SECTION 4-8 ~~Matters Related~~– ~~to Accountants and Financial Statements~~OTHER EVENTS

Item 48.01 ~~Changes~~– inOther ~~Registrant’s Certifying Accountant~~Events.

On January 612, 2016, wethe ~~dismissed~~Financial ~~KLJ &~~Industry ~~Associates,~~Regulatory ~~LLP~~Authority (~~the “Former Accountant”~~FINRA) asconfirmed ~~our~~that ~~independent~~the ~~auditor.~~market ~~Also~~effective ondate ~~January~~of ~~6, 2016,~~ our ~~board~~recent ofname ~~directors appointed~~change ~~RBSM,~~to ~~LLP (the~~ “~~New~~Microlin ~~Accountant”)~~Bio, ~~as our new independent registered public accounting firm~~Inc. ~~The Former Accountant~~” ~~served~~will asbe ~~the~~January ~~independent~~14, ~~auditor~~2016. ~~for~~Beginning ~~American~~January ~~Boarding~~14, ~~Company~~2016, ~~and~~our ~~has~~common ~~been~~stock ~~dismissed~~will inhave ~~favor of~~ the ~~New~~following ~~Accountant,~~new ~~who~~CUSIP ~~has served~~number asand ~~the~~new ~~independent auditor for our recent accounting acquirer, Microlin Bio, Inc.~~trading symbol:

~~The~~New ~~Former~~CUSIP Accountant’s audit reports on the financial statements for our former fiscal years ended December 31, 2014 and 2013, contained no adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles, with exception of uncertainty regarding our ability to continue as a going concern.Number: 59508L106

~~During~~New ~~the~~Trading ~~former~~Symbol: fiscal years ended December 31, 2014 and 2013 and through the interim periods ended January 6, 2016, there were no “disagreements” (as such term is defined in Item 304 of Regulation S-K) with the Former Accountant on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements if not resolved to the satisfaction of the Former Accountant would have caused them to make reference thereto in their reports on the financial statements for such periods.MICB

During the former fiscal years ended December 31, 2014 and 2013 and through the interim periods ended January 6, 2016, there were the following “reportable events” (as such term is defined in Item 304 of Regulation S-K). As disclosed in Part II, Item 9A of the Company’s Form 10-K for the former fiscal year ended December 31, 2014, the Company’s management determined that the Company’s internal controls over financial reporting were not effective as of the end of such period due to the existence of material weaknesses related to the following:SIGNATURES

~~(i)~~Pursuant ~~lack~~to the requirements of anthe ~~audit~~Securities Exchange ~~committee;~~Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~(ii)~~Microlin ~~lack~~Bio, ~~of a majority of outside directors on our board of directors; and~~Inc.

~~(iii) management dominated by a single individual~~/~~small~~s/ ~~group~~Joseph ~~without adequate compensating controls.~~Hernandez

~~These~~Joseph ~~material weaknesses have not been remediated~~Hernandez asExecutive ~~of the date of this Current Report on Form 8-K.~~Chairman

~~Other~~Date: ~~than as disclosed above, there were no reportable events during the former fiscal years ended December 31, 2014 and 2013 and through the interim periods ended~~ January 6, ~~2016. We authorized the Former Accountant to respond fully and without limitation to all requests of the New Accountant concerning all matters related to the audited period by the Former Accountant~~12, ~~including with respect to the subject matter of each reportable event.~~2016

Prior to retaining the New Accountant, we did not consult with the New Accountant regarding either: (i) the application of accounting principles to a specified transaction, either contemplated or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements; or (ii) any matter that was the subject of a “disagreement” or a “reportable event” (as those terms are defined in Item 304 of Regulation S-K).2

On January 6, 2016, the Company provided the Former Accountant with its disclosures in this Current Report on Form 8-K disclosing the dismissal of the Former Accountant and requested in writing that the Former Accountant furnish us with a letter addressed to the Securities and Exchange Commission stating whether or not they agree with such disclosures. The Former Accountant’s response is filed as an exhibit to this Current Report on Form 8-K.

SECTION 9 – Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

Exhibit No.	Description
16.1	Letter from KLJ & Associates, LLP to the Securities and Exchange Commission

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Microlin Bio, Inc.

/s/ Joseph Hernandez

Joseph Hernandez Executive Chairman

Date: January 6, 2016

Filing Compare · Microlin Bio, Inc